LOGIN  |  REGISTER
Recursion

DocGo Announces Upcoming Participation at Canaccord Genuity 43rd Annual Growth Conference

July 31, 2023 | Last Trade: US$1.50 0.06 -3.85

NEW YORK / Jul 31, 2023 / Business Wire / DocGo Inc (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that Anthony Capone, Chief Executive Officer will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9 at 8:30 AM Eastern Time. A webcast of the event will be available on the investor relations section of DocGo’s website at https://ir.docgo.com/.

About DocGo

DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's proprietary, AI-powered technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page